Eli Lilly CEO Dave Ricks reported that 700,000 new seniors enrolled in GLP-1 obesity treatments through Medicare coverage since July, with 70% using Lilly drugs. Lilly's Zepbound injection and newly launched Foundayo pill are capturing the majority of new patients, with Ricks attributing success to physician preference for treating patients with higher weight and complications.